lb-30057 and Thrombosis

lb-30057 has been researched along with Thrombosis* in 1 studies

Other Studies

1 other study(ies) available for lb-30057 and Thrombosis

Article	Year
Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor. Bioorganic & medicinal chemistry letters, 1998, Mar-17, Volume: 8, Issue:6 Systematic variation of the so-called P-pocket moiety of benzamidrazone-based selective thrombin inhibitors led to the discovery of LB30057. It is potent (Ki = 0.38 nM for human thrombin), selective (Ki = 3290 nM for bovine trypsin), and orally bioavailable (58% oral bioavailability in dogs). LB30057 was efficacious in thrombosis animal models. Topics: Animals; Benzamides; Biological Availability; Cattle; Disease Models, Animal; Dogs; Half-Life; Humans; Models, Molecular; Rats; Structure-Activity Relationship; Thrombin; Thrombosis	1998

Article

Year

Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor.

Bioorganic & medicinal chemistry letters, 1998, Mar-17, Volume: 8, Issue:6

Systematic variation of the so-called P-pocket moiety of benzamidrazone-based selective thrombin inhibitors led to the discovery of LB30057. It is potent (Ki = 0.38 nM for human thrombin), selective (Ki = 3290 nM for bovine trypsin), and orally bioavailable (58% oral bioavailability in dogs). LB30057 was efficacious in thrombosis animal models.

Topics: Animals; Benzamides; Biological Availability; Cattle; Disease Models, Animal; Dogs; Half-Life; Humans; Models, Molecular; Rats; Structure-Activity Relationship; Thrombin; Thrombosis

1998